MARK1
Serine/threonine-protein kinase MARK1
Also known as: MARK, MARK1_HUMAN, PAR-1C
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9P0L2
- Gene
- MARK1
- Ensembl
- ENSG00000116141
- Chromosome
- 1
- Canonical length
- 795 aa
- Protein class
- Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins
OverviewNCBI Gene
Enables several functions, including ATP binding activity; magnesium ion binding activity; and phospholipid binding activity. Involved in intracellular signal transduction; negative regulation of epithelial to mesenchymal transition; and protein phosphorylation. Located in cytoplasm; dendrite; and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
795 residues, UniProt reviewed canonical sequence.
>Q9P0L2|MARK1
1 MSARTPLPTV NERDTENHTS VDGYTEPHIQ PTKSSSRQNI PRCRNSITSA TDEQPHIGNY
61 RLQKTIGKGN FAKVKLARHV LTGREVAVKI IDKTQLNPTS LQKLFREVRI MKILNHPNIV
121 KLFEVIETEK TLYLVMEYAS GGEVFDYLVA HGRMKEKEAR AKFRQIVSAV QYCHQKYIVH
181 RDLKAENLLL DGDMNIKIAD FGFSNEFTVG NKLDTFCGSP PYAAPELFQG KKYDGPEVDV
241 WSLGVILYTL VSGSLPFDGQ NLKELRERVL RGKYRIPFYM STDCENLLKK LLVLNPIKRG
301 SLEQIMKDRW MNVGHEEEEL KPYTEPDPDF NDTKRIDIMV TMGFARDEIN DALINQKYDE
361 VMATYILLGR KPPEFEGGES LSSGNLCQRS RPSSDLNNST LQSPAHLKVQ RSISANQKQR
421 RFSDHAGPSI PPAVSYTKRP QANSVESEQK EEWDKDVARK LGSTTVGSKS EMTASPLVGP
481 ERKKSSTIPS NNVYSGGSMA RRNTYVCERT TDRYVALQNG KDSSLTEMSV SSISSAGSSV
541 ASAVPSARPR HQKSMSTSGH PIKVTLPTIK DGSEAYRPGT TQRVPAASPS AHSISTATPD
601 RTRFPRGSSS RSTFHGEQLR ERRSVAYNGP PASPSHETGA FAHARRGTST GIISKITSKF
661 VRRDPSEGEA SGRTDTSRST SGEPKERDKE EGKDSKPRSL RFTWSMKTTS SMDPNDMMRE
721 IRKVLDANNC DYEQKERFLL FCVHGDARQD SLVQWEMEVC KLPRLSLNGV RFKRISGTSI
781 AFKNIASKIA NELKLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MARK1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 9.7 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 9.7 nTPM
- epididymis: 9.1 nTPM
- retina: 8.6 nTPM
- cerebellum: 7.7 nTPM
- heart muscle: 7.5 nTPM
- hypothalamus: 6.8 nTPM
Single-cell type
- choroid plexus epithelial cells: 551 nCPM
- urothelial cells: 338 nCPM
- endometrial glandular cells: 319 nCPM
- retinal ganglion cells: 274 nCPM
- adipocytes: 271 nCPM
- retinal bipolar cells: 251 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 13 nTPM
- cerebral cortex: 12 nTPM
- pons: 10 nTPM
- basal ganglia: 8.8 nTPM
- midbrain: 8.8 nTPM
- hypothalamus: 8.7 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.36
- gnomAD pLI
- 0.6
- gnomAD missense Z
- 2.73
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cytoskeleton organization
- establishment of mitochondrion localization
- intracellular signal transduction
- microtubule cytoskeleton organization
- negative regulation of epithelial to mesenchymal transition
- negative regulation of gene expression
- neuron migration
- positive regulation of gene expression
- protein phosphorylation
- regulation of dendrite development
- regulation of neuron projection development
- regulation of postsynapse assembly
- Wnt signaling pathway
Molecular functions
- ATP binding
- magnesium ion binding
- phosphatidic acid binding
- phosphatidylinositol-4,5-bisphosphate binding
- phosphatidylserine binding
- protein serine kinase activity
- protein serine/threonine kinase activity
- tau protein binding
- tau-protein kinase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Kinase associated domain 1 (KA1)
- Serine/threonine-protein kinase, active site
- Protein kinase-like domain superfamily
- Ubiquitin-associated domain
- Protein kinase, ATP binding site
- KA1 domain/Ssp2, C-terminal
- Serine/threonine-protein kinase MARK 1-4, catalytic domain
- Protein kinase domain
- UBA/TS-N domain
- Kinase associated domain 1
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MARK1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MARK1 as an antibody target. Whether an autoantibody or antibody against MARK1 could matter depends on whether native MARK1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MARK1 is annotated at the cell surface, where native MARK1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MARK1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...